Collegium Pharmaceutical, Inc. (NASDAQ:COLL)‘s stock had its “buy” rating reissued by equities researchers at Jefferies Group LLC in a research note issued on Friday. They presently have a $15.00 target price on the specialty pharmaceutical company’s stock. Jefferies Group LLC’s price target points to a potential upside of 31.81% from the stock’s previous close.

Several other research analysts also recently commented on COLL. Zacks Investment Research raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $14.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, September 8th. Needham & Company LLC reissued a “buy” rating and set a $25.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, June 9th. Janney Montgomery Scott reissued a “buy” rating and set a $25.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, June 12th. Finally, ValuEngine raised shares of Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $20.00.

Shares of Collegium Pharmaceutical (NASDAQ:COLL) opened at 11.38 on Friday. The firm’s market capitalization is $336.46 million. The stock’s 50 day moving average is $10.46 and its 200 day moving average is $10.46. Collegium Pharmaceutical has a 52-week low of $9.27 and a 52-week high of $18.67.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.09. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 93.73%. The company had revenue of $3.56 million for the quarter, compared to the consensus estimate of $4.07 million. On average, equities research analysts forecast that Collegium Pharmaceutical will post ($3.00) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Jefferies Group LLC Reiterates Buy Rating for Collegium Pharmaceutical, Inc. (COLL)” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/06/jefferies-group-llc-reiterates-buy-rating-for-collegium-pharmaceutical-inc-coll.html.

Several large investors have recently added to or reduced their stakes in COLL. American International Group Inc. grew its position in shares of Collegium Pharmaceutical by 27.8% in the 1st quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after buying an additional 2,163 shares during the period. Nationwide Fund Advisors grew its position in shares of Collegium Pharmaceutical by 16.4% in the 1st quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 1,422 shares during the period. Voya Investment Management LLC purchased a new stake in shares of Collegium Pharmaceutical in the 2nd quarter worth about $125,000. Credit Suisse AG grew its position in shares of Collegium Pharmaceutical by 9.4% in the 1st quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 1,173 shares during the period. Finally, UBS Group AG grew its position in shares of Collegium Pharmaceutical by 283.2% in the 1st quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock worth $139,000 after buying an additional 10,174 shares during the period. 83.04% of the stock is currently owned by hedge funds and other institutional investors.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.